bioAffinity Technologies Inc (BIAF)

[hondaboost]

BIAF, $0.32, amazing news for Lung Cancer:

Case Study: CyPath(TM) Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules

2025-09-09 08:00 ET - News Release


bioAffinity Technologies’ noninvasive diagnostic shifted the course of care from watchful waiting for up to 5 years to confirmed malignancy and immediate treatment


Company Website: http://www.bioaffinitytech.com
SAN ANTONIO -- (Business Wire)

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released another compelling case study in which its flagship product, CyPath® Lung, identified cancer in a patient with an incidental finding of ground-glass lung nodules.

Ground-glass nodules appear in imaging as hazy gray areas distinct from solid nodules. Clinicians often find them challenging to assess because they can remain stable for many years, often mimic benign lesions caused by inflammation or fibrosis, and typically do not light up on PET scans.

“Society guidelines for ground-glass nodules recommend two to five years of watchful waiting with serial CT scans. Obviously, this can put both patients and their doctors in an uncomfortable position of balancing uncertainty against the risks of delayed diagnosis,” said Gordon Downie, MD, PhD, bioAffinity Technologies’ Chief Medical Officer. “Adding CyPath® Lung to the traditional standard of care can provide actionable results that move beyond watchful waiting to timely, potentially life-saving treatment.”